Recent updates to the McDonald criteria — the internationally recognized guidelines used to diagnose multiple sclerosis (MS) — may support earlier and more accurate diagnoses. But the changes are also expected to require researchers to rethink how clinical trials testing new MS therapies are run, and better biomarkers…

AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…

A research team at the University of California, Los Angeles (UCLA) has received a $7.49 million grant to advance a novel cell-based therapy for multiple sclerosis (MS) toward its first clinical trial. The state funding, awarded by the California Institute for Regenerative Medicine (CIRM), was earmarked for a team…

Increasing the dose of the infusion therapy Ocrevus (ocrelizumab) does not provide additional benefit compared with the approved regimen in slowing disability progression for people with relapsing forms of multiple sclerosis (MS) or primary progressive MS. That’s according to final data from two global Phase 3b clinical…

The U.S. Food and Drug Administration (FDA) has given Pheno Therapeutics the green light to begin clinical testing of PTD802, the company’s oral lead treatment candidate for boosting myelin repair in people with multiple sclerosis (MS) and other neurological diseases. The experimental remyelination therapy aims to potentially…

Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug…

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Quantum Biopharma’s application seeking clearance to begin a Phase 2 trial testing Lucid-MS in people with multiple sclerosis (MS). Quantum said the FDA requested further information before clearing the investigational new drug (IND) application and…

First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses, reduced signs of MRI disease activity, and better disability outcomes compared with those given the older drug Aubagio (teriflunomide) as their initial therapy.

Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), a form of multiple sclerosis (MS) with limited treatment options. “Reaching full enrollment in this landmark study is a testament to the strong…

Liberate Bio’s investigational CAR-M cell therapy LIB820 may help successfully eliminate disease-driving B-cells in autoimmune diseases such as multiple sclerosis (MS) without causing severe side effects, according to new preclinical data. The therapy is designed to genetically engineer two types of immune cells — monocytes and macrophages — within…